← Oncology Approval Tracker

FDA DECISION ·

Rybrevant Faspro

amivantamab and hyaluronidase-lpuj · Janssen Biotech

Accelerated approvalNew or expanded indicationHead and neck cancer
Open LinkedIn brief ↓

1 min read · estimated

Sources

APPROVED USE

What FDA approved

Subcutaneous monotherapy for adults with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) after progression on or following platinum chemotherapy and an anti-PD-(L)1 antibody. The use excludes HPV-associated oropharyngeal squamous cell carcinoma.

SUPPORTING DATA

Evidence behind the decision

Study
OrigAMI-4 was a multicenter, open-label study. The primary HNSCC efficacy group included 102 patients.
Key result
Independent review found a 42% overall response rate (95% CI, 32%–52%). Of responders, 56% maintained a response for at least six months.
Safety to report
FDA labeling flags administration reactions and hypersensitivity, ILD or pneumonitis, skin reactions and ocular toxicity.
Evidence limits
The efficacy group had no randomized comparator. Response and duration of response do not establish a comparative survival benefit.

LAMPGEN ANALYSIS

Why it matters

This adds an EGFR–MET bispecific option for a heavily treated head and neck cancer population. The activity reported in OrigAMI-4 gives a reason to follow the confirmatory work and the durability of response.

What research teams should watch

The label makes prior platinum and checkpoint therapy, progression timing and HPV-associated oropharyngeal status important source-document checks. Confirmatory teams also need consistent response assessment and toxicity escalation.

Clinical operations takeaway

Build the monitoring checklist around protocol-specific eligibility and source documentation for prior treatment. Give sites a named contact for resolving conflicting or incomplete records before eligibility review.

Evaluate protocol-specific oncology experience

PRIMARY RECORDS

Sources